Skip to search formSkip to main contentSkip to account menu

Study of Tamoxifen and Raloxifene (STAR)

Known as: STAR, Study of Tamoxifen and Raloxifene 
Part of the National Surgical Adjuvant Breast and Bowel Project. A study to compare the efficacy of Tamoxifen to Raloxifene in prevention of primary… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
PURPOSE The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the… 
Highly Cited
2010
Highly Cited
2010
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)–approved… 
Review
2009
Review
2009
  • V. Vogel
  • Expert review of anticancer therapy
  • 2009
  • Corpus ID: 4828650
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either… 
2009
2009
PURPOSE To compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain… 
Highly Cited
2007
Highly Cited
2007
BACKGROUND The Breast Cancer Risk Assessment Tool of the National Cancer Institute (NCI) is widely used for counseling and… 
Highly Cited
2006
Highly Cited
2006
CONTEXT Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast… 
Review
2006
Review
2006
ContextTamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with… 
Review
2006
Review
2006
CONTEXT Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with… 
Review
1999
Review
1999
I. Introduction II. Lacassagne’s Prevention Principle: A Target and an Estrogen Antagonist III. Tamoxifen as an Antitumor Agent A…